Dulaglutide: Uses, Mechanism, and Side Effects

Managing type 2 diabetes often means balancing blood sugar control with cardiovascular health. Dulaglutide, sold under the brand name Trulicity, is a prescription medicine designed to address both.

Key takeaways

• Dulaglutide is a GLP-1 receptor agonist approved for type 2 diabetes and cardiovascular risk reduction.
• It is approved for adults and pediatric patients 10 years of age and older for glycemic control.
• The label carries a boxed warning.
• More than 150 registered trials have studied dulaglutide, including phase 3 and phase 4 work.
• The most commonly reported issues involve nausea, injection site pain, and gastrointestinal upset.

What Dulaglutide Is

Dulaglutide belongs to a class of medicines called GLP-1 receptor agonists. It shares 90% amino acid sequence homology with the body's own GLP-1 hormone. By activating the GLP-1 receptor on pancreatic beta cells, dulaglutide raises intracellular cAMP, which triggers glucose-dependent insulin release. It also lowers glucagon secretion and slows gastric emptying, actions that together help regulate blood sugar.

What Dulaglutide Is Approved For

Sold as Trulicity, dulaglutide is approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. It is also approved to reduce the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. The prescribing label for dulaglutide includes a boxed warning.

What The Evidence Shows

Dulaglutide has been studied in more than 150 registered clinical trials. A completed phase 3 study compared two doses of dulaglutide in Japanese patients with type 2 diabetes. A separate completed phase 4 trial examined GLP-1 receptor agonists, including dulaglutide, in patients with polycystic ovary syndrome. An earlier phase 1 study assessed dulaglutide alongside sitagliptin in people with type 2 diabetes.

Reported Side Effects

Reports submitted to the FDA's adverse event system, which reflect raw report counts rather than confirmed incidence or causation, show a pattern dominated by gastrointestinal and injection-related complaints. Nausea (10,580 reports) and injection site pain (10,019) are the most frequently reported terms, followed by diarrhoea (6,200) and vomiting (5,949). Blood glucose increased was also reported frequently (9,960), alongside administration issues such as incorrect dose administered (5,663) and inappropriate scheduling of the product (3,843). Reports of the drug being ineffective (3,757) were also logged.